CL2021003326A1 - Anticuerpo anti-epha4 humano. - Google Patents

Anticuerpo anti-epha4 humano.

Info

Publication number
CL2021003326A1
CL2021003326A1 CL2021003326A CL2021003326A CL2021003326A1 CL 2021003326 A1 CL2021003326 A1 CL 2021003326A1 CL 2021003326 A CL2021003326 A CL 2021003326A CL 2021003326 A CL2021003326 A CL 2021003326A CL 2021003326 A1 CL2021003326 A1 CL 2021003326A1
Authority
CL
Chile
Prior art keywords
epha4
antibody
epha4 antibody
human anti
mouse anti
Prior art date
Application number
CL2021003326A
Other languages
English (en)
Inventor
Toshio Imai
Eiji Inoue
Aki Nakatani
Akio Yamada
Tomomi Kawakatsu
Maki Deguchi
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2021003326A1 publication Critical patent/CL2021003326A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporciona un anticuerpo anti-EphA4 que puede unirse a EphA4 y potenciar la escisión de EphA4, así como una composición farmacéutica que comprende el anticuerpo como el principio activo. Se obtuvo un anticuerpo anti-EphA4 de ratón que tiene afinidad de unión hacia EphA4 y puede potenciar la escisión de EphA4, y se identificó la secuencia de la región determinante de complementariedad (CDR) del anticuerpo anti-EphA4 de ratón. Posteriormente, se obtuvo el anticuerpo anti-EphA4 de interés produciendo un anticuerpo humanizado del anticuerpo anti-EphA4 de ratón.
CL2021003326A 2019-07-01 2021-12-13 Anticuerpo anti-epha4 humano. CL2021003326A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019122982 2019-07-01

Publications (1)

Publication Number Publication Date
CL2021003326A1 true CL2021003326A1 (es) 2022-07-22

Family

ID=74066003

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003326A CL2021003326A1 (es) 2019-07-01 2021-12-13 Anticuerpo anti-epha4 humano.

Country Status (23)

Country Link
US (2) US10947313B2 (es)
EP (1) EP3995582B1 (es)
JP (2) JP6979147B2 (es)
KR (1) KR102953475B1 (es)
CN (2) CN113906050B (es)
AR (1) AR119303A1 (es)
AU (1) AU2020300205B2 (es)
BR (1) BR112021025161A2 (es)
CA (1) CA3139398A1 (es)
CL (1) CL2021003326A1 (es)
CO (1) CO2021016588A2 (es)
IL (1) IL287828A (es)
JO (1) JOP20210333A1 (es)
MA (1) MA56466A (es)
MX (1) MX2021015298A (es)
MY (1) MY207780A (es)
PE (1) PE20220570A1 (es)
PH (1) PH12021553090A1 (es)
SG (1) SG11202112433VA (es)
TW (3) TWI808882B (es)
UA (1) UA129772C2 (es)
WO (1) WO2021002312A1 (es)
ZA (1) ZA202108836B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
EP3995582B1 (en) 2019-07-01 2026-04-22 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
US20240010735A1 (en) * 2020-12-24 2024-01-11 Eisai R&D Management Co., Ltd. Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis
AU2022388189A1 (en) * 2021-11-11 2024-05-02 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
WO2025151607A1 (en) * 2024-01-10 2025-07-17 Santa Ana Bio, Inc. Methods and compositions for treating autoimmune, allergic and inflammatory diseases

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1094731A (en) 1911-06-06 1914-04-28 Lucien Linden Oxidizing process.
JP2824433B2 (ja) 1988-12-09 1998-11-11 財団法人化学及血清療法研究所 新規なハイブリッドプロモーターおよびこれを組み込んだ外来遺伝子発現用ベクター
CA1339413C (en) 1988-06-24 1997-09-02 Junichi Miyazaki Exogenous gene expression vector containing chick .beta.-actin gene promoter
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5902732A (en) 1995-10-04 1999-05-11 Cytoscan Sciences Llc Drug screening process measuring changes in cell volume
US20020068361A1 (en) 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US5876946A (en) 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
US20060241074A1 (en) 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
US20070026409A1 (en) 2001-08-14 2007-02-01 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
EP1478772A2 (en) 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
JP2003169699A (ja) 2001-12-10 2003-06-17 Japan Science & Technology Corp 特異的γプロテアーゼ阻害剤のスクリーニング方法
JP2004000060A (ja) 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
WO2004028551A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
HRP20050461A2 (en) 2002-11-26 2005-08-31 Pharmacia & Upjohn Company Llc Soluble notch-based substrates for gamma secretase and methods and compositions for using same
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
EP1693449A4 (en) 2003-11-10 2007-07-25 Osaka Ind Promotion Org CELL-FREE NOTCH CLEAVAGE ANALYSIS PROCEDURE AND DRUG SCREENING METHOD
JP2007525203A (ja) 2004-02-27 2007-09-06 オンコセラピー・サイエンス株式会社 ＰＲＣおよびＰＤＡＣａの治療標的としてのＥｐｈＡ４
WO2006026820A1 (en) 2004-09-08 2006-03-16 The University Of Queensland Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor
EP1662259A1 (en) 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
GB0427023D0 (en) 2004-12-09 2005-01-12 Merck Sharp & Dohme Assay method
EP2004228A1 (en) 2006-02-28 2008-12-24 Oncotherapy Science, Inc. Methods for damaging cells using effector functions of anti-epha4 antibodies
EP1947193A1 (en) 2007-01-17 2008-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening method for anti-diabetic compounds
WO2008150010A1 (ja) 2007-06-08 2008-12-11 Eisai R & D Management Co., Ltd. γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法
US20090023158A1 (en) 2007-07-13 2009-01-22 Elan Pharmaceuticals, Inc. Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase
EP2177623A4 (en) 2007-07-19 2010-12-29 Eisai R&D Man Co Ltd SCREENING METHOD USING C-MET, A NEW SUBSTRATE FOR GAMMA SECRETASE
EP2192181A4 (en) 2007-08-01 2010-12-08 Eisai R&D Man Co Ltd SCREENING METHOD USING THE NEW C-RET SUBSTRATE FOR GAMMA-SECRETASE
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
US20090163594A1 (en) 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
JP5580598B2 (ja) 2007-11-15 2014-08-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 γ−セクレターゼの新規基質ＥｐｈＡ７を利用したスクリーニング方法
EP2223999B1 (en) 2007-11-30 2017-10-18 Eisai R&D Management Co., Ltd. Epha4 polypeptide having novel activity and use thereof
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
JP2010285413A (ja) 2009-06-10 2010-12-24 Univ Of Melbourne 治療用途
EP2260864A1 (en) 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications
EP2653552B1 (en) 2010-12-17 2016-10-19 Eisai R&D Management Co., Ltd. SCREENING METHOD USING GELATINASE-MEDIATED EphA4 CLEAVAGE REACTION AS AN INDICATOR
US9784751B2 (en) 2011-04-25 2017-10-10 Eisai R&D Management Co., Ltd. Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain
GB201107996D0 (en) 2011-05-13 2011-06-29 Vib Vzw EphA4 is a diease modifier in motor neuron disease
WO2015007222A1 (en) * 2013-07-17 2015-01-22 The Hong Kong University Of Science And Technology EphA4 INHIBITORS AS NEUROPROTECTIVE AGENTS
WO2016019280A1 (en) 2014-07-31 2016-02-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies against epha4 and their use
CA2989993A1 (en) * 2015-09-08 2017-03-16 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
EP3995582B1 (en) 2019-07-01 2026-04-22 Eisai R&D Management Co., Ltd. Anti-epha4 antibody

Also Published As

Publication number Publication date
JP6979147B2 (ja) 2021-12-08
AU2020300205B2 (en) 2026-03-19
NZ783106A (en) 2025-08-29
ZA202108836B (en) 2023-04-26
MX2021015298A (es) 2022-01-18
US10947313B2 (en) 2021-03-16
WO2021002312A1 (ja) 2021-01-07
IL287828A (en) 2022-01-01
AU2020300205A1 (en) 2022-01-20
PH12021553090A1 (en) 2022-07-25
CN117398459A (zh) 2024-01-16
CN113906050A (zh) 2022-01-07
TWI808882B (zh) 2023-07-11
US11136400B2 (en) 2021-10-05
EP3995582A4 (en) 2023-01-18
KR102953475B1 (ko) 2026-04-16
TW202342101A (zh) 2023-11-01
TW202248216A (zh) 2022-12-16
BR112021025161A2 (pt) 2022-01-25
TWI866304B (zh) 2024-12-11
SG11202112433VA (en) 2021-12-30
EP3995582B1 (en) 2026-04-22
US20210002378A1 (en) 2021-01-07
MY207780A (en) 2025-03-18
KR20220027825A (ko) 2022-03-08
JOP20210333A1 (ar) 2021-12-14
CO2021016588A2 (es) 2022-04-08
AR119303A1 (es) 2021-12-09
CN113906050B (zh) 2023-11-21
US20210171644A1 (en) 2021-06-10
TW202115116A (zh) 2021-04-16
TWI779307B (zh) 2022-10-01
JP7072114B2 (ja) 2022-05-19
PE20220570A1 (es) 2022-04-20
CA3139398A1 (en) 2021-01-07
MA56466A (fr) 2022-05-11
EP3995582A1 (en) 2022-05-11
JPWO2021002312A1 (ja) 2021-09-13
JP2022031271A (ja) 2022-02-18
UA129772C2 (uk) 2025-07-30

Similar Documents

Publication Publication Date Title
CO2021016588A2 (es) Anticuerpo anti-epha4 humano
AR104250A1 (es) Anticuerpo anti-notch4 humano
ZA202106131B (en) Bcma monoclonal antibody-drug conjugate
CL2021000458A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr (divisional de solicitud 201602359)
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
MX2020013348A (es) Anticuerpos biespecificos contra dll3-cd3.
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
ECSP19029942A (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
CO2018000652A2 (es) Anticuerpo anti-epha4
MX2018015280A (es) Conjugados de anticuerpo y farmaco anti-egfr.
MX368996B (es) Formulaciones de anticuerpos y usos de las mismas.
MX2019013071A (es) Metodo de tratamiento inmunoterapeutico de un tumor.
EA202092849A1 (ru) Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
MX2020003034A (es) Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.